Retif Paul, Verrecchia-Ramos Emilie, Saleh Motchy, Djibo Sidikou Abdourahamane, Letellier Romain, Al Salah Anwar, Pfletschinger Estelle, Taesch Fabian, Ben-Mahmoud Sinan, Michel Xavier
Medical Physics Unit, Centre Hospitalier Régional Metz-Thionville, 57000 Metz, France.
Université de Lorraine, Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Automatique de Nancy (CRAN), 54000 Nancy, France.
J Clin Med. 2025 Jun 6;14(12):4015. doi: 10.3390/jcm14124015.
The re-irradiation of centrally located lung tumors poses substantial risks due to prior dose exposure and proximity to critical structures. Accurate target delineation is crucial to minimize toxicity and ensure tumor coverage. Four-dimensional positron emission tomography/computed tomography (4D-PET/CT) integrates respiratory motion and metabolic data, offering improved delineation over static imaging. Its clinical utility in re-irradiation remains under-reported. A 67-year-old male presented with the central recurrence of squamous cell carcinoma in the right upper lobe, embedded in radiation-induced fibrosis, following prior chemoradiotherapy. Delineation using static PET underestimated tumor motion. A 4D-PET/CT-guided Stereotactic Body Radiation Therapy (SBRT) plan was developed with a prescription of 60 Gy in eight fractions. A comparative plan using static PET was generated to assess the dosimetric differences. The internal target volume (ITV) from 4D-PET/CT was nearly double the size of the GTV from static PET, with a 5.1 mm discrepancy in the craniocaudal axis. The 4D-PET-based plan achieved 95.0% PTV coverage, while the static PET-based plan covered only 61.7%, illustrating the risk of underdosage without motion-resolved imaging. The patient completed the treatment without acute or late toxicity and showed a sustained metabolic response at one year (SUVmax from 13.4 to 5.8). This case demonstrates the clinical value of 4D-PET/CT in the SBRT re-irradiation of centrally located lung tumors, particularly in fibrotic regions where anatomical imaging is insufficient. It enabled accurate delineation, improved dosimetric coverage, and safe, effective retreatment. These findings support its integration into planning for complex thoracic re-irradiation.
由于先前的剂量暴露以及与关键结构的接近程度,对位于中央的肺部肿瘤进行再照射存在重大风险。准确的靶区勾画对于将毒性降至最低并确保肿瘤覆盖至关重要。四维正电子发射断层扫描/计算机断层扫描(4D-PET/CT)整合了呼吸运动和代谢数据,与静态成像相比能提供更好的勾画效果。其在再照射中的临床应用报道仍较少。一名67岁男性,既往接受放化疗后,右肺上叶出现鳞状细胞癌中央复发,肿瘤包埋于放射性纤维化组织中。使用静态PET进行的勾画低估了肿瘤运动。制定了一个4D-PET/CT引导的立体定向体部放射治疗(SBRT)计划,处方剂量为60 Gy,分8次照射。生成了一个使用静态PET的对比计划以评估剂量差异。4D-PET/CT确定的内部靶区体积(ITV)几乎是静态PET确定的大体肿瘤体积(GTV)的两倍,在头尾轴上相差5.1 mm。基于4D-PET的计划实现了95.0%的计划靶区体积(PTV)覆盖,而基于静态PET的计划仅覆盖了61.7%,这说明了在没有运动分辨成像的情况下存在剂量不足的风险。患者完成治疗后未出现急性或晚期毒性反应,且在一年时显示出持续的代谢反应(最大标准摄取值从13.4降至5.8)。该病例证明了4D-PET/CT在中央型肺部肿瘤SBRT再照射中的临床价值,特别是在解剖成像不足的纤维化区域。它能够实现准确的勾画,改善剂量覆盖,并进行安全、有效的再治疗。这些发现支持将其纳入复杂胸部再照射的计划中。